{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:28:36Z","timestamp":1792578516402,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.nano.2026.102910","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T17:23:38Z","timestamp":1770657818000},"page":"102910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cisplatin(IV)-fatty acid prodrug-bound albumin nanoparticles: In vitro, in silico, and in vivo evaluation in breast cancer therapy"],"prefix":"10.1016","volume":"72","author":[{"given":"Oly","family":"Katari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajkumar","family":"R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanyog","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2026.102910_bb0005","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1074\/jbc.273.24.14721","article-title":"Cisplatin binding sites on human albumin","volume":"273","author":"Ivanov","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nano.2026.102910_bb0010","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/mp2000583","article-title":"Effects of noncovalent platinum drug\u2013protein interactions on drug efficacy: use of fluorescent conjugates as probes for drug metabolism","volume":"8","author":"Benedetti","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2026.102910_bb0015","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8276139","article-title":"Current developments in Pt(IV) prodrugs conjugated with bioactive ligands","volume":"2018","author":"Li","year":"2018","journal-title":"Bioinorg Chem Appl"},{"key":"10.1016\/j.nano.2026.102910_bb0020","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ejmech.2017.08.010","article-title":"Prodrug strategy for cancer cell-specific targeting: a recent overview","volume":"139","author":"Zhang","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.nano.2026.102910_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172937","article-title":"Anticancer activities of fatty acids and their heterocyclic derivatives","volume":"871","author":"J\u00f3\u017awiak","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nano.2026.102910_bb0030","doi-asserted-by":"crossref","first-page":"8790","DOI":"10.1021\/ja5038269","article-title":"Pt (IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery","volume":"136","author":"Zheng","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.nano.2026.102910_bb0035","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13346-023-01415-7","article-title":"Exploring the synergistic behavior of paclitaxel and vorinostat upon co-loading in albumin nanoparticles for breast cancer management","volume":"14","author":"Abhang","year":"2024","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.nano.2026.102910_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.846175","article-title":"Albumin-based nanocarriers for the simultaneous delivery of antioxidant gene and phytochemical to combat oxidative stress","volume":"10","author":"Naqvi","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.nano.2026.102910_bb0045","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acs.molpharmaceut.1c00844","article-title":"Understanding the role of axial ligands in modulating the biopharmaceutical outcomes of cisplatin(IV) derivatives","volume":"19","author":"Date","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2026.102910_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123570","article-title":"Genipin-crosslinked albumin nanoparticles containing neratinib and silibinin: a dual-death therapy for triple negative breast cancer","volume":"648","author":"Ghadi","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.102910_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-025-01833-9","article-title":"Dual acting oxaliplatin (IV) prodrug loaded albumin nanoparticles for safer synergistic anticancer action against triple negative breast cancer","author":"Abhang","year":"2025","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.nano.2026.102910_bb0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0928-0987(00)00169-X","article-title":"Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties","volume":"12","author":"Merodio","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.nano.2026.102910_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1055356","article-title":"The copper transporter CTR1 and cisplatin accumulation at the single-cell level by LA-ICP-TOFMS","volume":"9","author":"Schoeberl","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.nano.2026.102910_bb0070","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3698391","article-title":"The strange case: the unsymmetric cisplatin-based Pt(IV) prodrug [Pt(CH3COO)Cl2(NH3)2(OH)] exhibits higher cytotoxic activity with respect to its symmetric congeners due to carrier-mediated cellular uptake","volume":"2022","author":"Gabano","year":"2022","journal-title":"Bioinorg Chem Appl"},{"key":"10.1016\/j.nano.2026.102910_bb0075","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1039\/D3QI00968H","article-title":"Tumor-targeted dual-action NSAID-platinum(IV) anticancer prodrugs","volume":"10","author":"Kastner","year":"2023","journal-title":"Inorg Chem Front"},{"key":"10.1016\/j.nano.2026.102910_bb0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: a review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J Nephrol"},{"key":"10.1016\/j.nano.2026.102910_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112328","article-title":"The role of natural antioxidants in cisplatin-induced hepatotoxicity","volume":"144","author":"Abd Rashid","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.102910_bb0090","series-title":"Haddad and Winchester\u2019s Clinical Management of Poisoning and Drug Overdose","first-page":"81","article-title":"Chapter 4 - principles of pharmacology","author":"Juurlink","year":"2007"},{"key":"10.1016\/j.nano.2026.102910_bb0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/NSA.S441324","article-title":"Factors affecting the synthesis of bovine serum albumin nanoparticles using the desolvation method","volume":"17","author":"Tanjung","year":"2024","journal-title":"Nanotechnol Sci Appl"},{"key":"10.1016\/j.nano.2026.102910_bb0100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/elps.1150050512","article-title":"The behavior of serum albumin upon isoelectric focusing on immobilized pH gradients","volume":"5","author":"Gianazza","year":"1984","journal-title":"Electrophoresis"},{"key":"10.1016\/j.nano.2026.102910_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102959","article-title":"Multifunctional nanoparticles from albumin for stimuli-responsive efficient dual drug delivery","volume":"88","author":"Nosrati","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.nano.2026.102910_bb0110","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3390\/cancers13123011","article-title":"Albumin-based nanoparticles for the delivery of doxorubicin in breast cancer","volume":"13","author":"Prajapati","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.nano.2026.102910_bb0115","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1080\/07391102.2019.1638303","article-title":"Interaction, cytotoxicity and sustained release assessment of a novel anti-tumor agent using bovine serum albumin nanocarrier","volume":"38","author":"Fattahian Kalhor","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.nano.2026.102910_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2021.102588","article-title":"Molecular modeling prediction of albumin-based nanoparticles and experimental preparation, characterization, and in-vitro release kinetics of prednisolone from the nanoparticles","volume":"64","author":"Kaboli","year":"2021","journal-title":"J Drug Delivery Sci Technol"},{"key":"10.1016\/j.nano.2026.102910_bb0125","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/pharmaceutics15122648","article-title":"Bovine serum albumin nanoparticles enhanced the intranasal bioavailability of silybin in rats","volume":"15","author":"Tartari","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102910_bb0130","article-title":"Label-free serum albumin nanoparticles for bioimaging and Trojan horse-like drug delivery","volume":"7","author":"Patra","year":"2022","journal-title":"J Sci Adv Mater Devices"},{"key":"10.1016\/j.nano.2026.102910_bb0135","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1039\/C7DT04614F","article-title":"The cisplatin-based Pt(IV)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions","volume":"47","author":"Gabano","year":"2018","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nano.2026.102910_bb0140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/annonc\/mdi090","article-title":"Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2\/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2\/neu oncogene amplification","volume":"16","author":"Menendez","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nano.2026.102910_bb0145","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s10495-007-0082-8","article-title":"Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation","volume":"12","author":"Bragado","year":"2007","journal-title":"Apoptosis"},{"key":"10.1016\/j.nano.2026.102910_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2024.106224","article-title":"Oleic acid inhibits the migration and invasion of breast cancer cells with stemness characteristics through oxidative stress-mediated attenuation of the FAK\/AKT\/NF-\u03baB pathway","volume":"116","author":"Kim","year":"2024","journal-title":"J Funct Foods"},{"key":"10.1016\/j.nano.2026.102910_bb0155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ab.2017.07.009","article-title":"Mitochondrial membrane potential","volume":"552","author":"Zorova","year":"2018","journal-title":"Anal Biochem"},{"key":"10.1016\/j.nano.2026.102910_bb0160","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3128","article-title":"Analysis of the mitochondrial membrane potential using the cationic JC-1 dye as a sensitive fluorescent probe","volume":"9","author":"Sivandzade","year":"2019","journal-title":"Bio Protoc"},{"key":"10.1016\/j.nano.2026.102910_bb0165","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nano.2026.102910_bb0170","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.3390\/cancers15225407","article-title":"Oleic acid exhibits anti-proliferative and anti-invasive activities via the PTEN\/AKT\/mTOR pathway in endometrial cancer","volume":"15","author":"Deng","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nano.2026.102910_bb0175","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/nar\/gkm032","article-title":"Mechanism of the formation of DNA\u2013protein cross-links by antitumor cisplatin","volume":"35","author":"Chv\u00e1lov\u00e1","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nano.2026.102910_bb0180","doi-asserted-by":"crossref","first-page":"12035","DOI":"10.1093\/nar\/gkab922","article-title":"Cisplatin fastens chromatin irreversibly even at a high chloride concentration","volume":"49","author":"Moon","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nano.2026.102910_bb0185","doi-asserted-by":"crossref","first-page":"F1678","DOI":"10.1152\/ajprenal.90424.2008","article-title":"Analysis of DNA breaks, DNA damage response, and apoptosis produced by high NaCl","volume":"295","author":"Dmitrieva","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nano.2026.102910_bb0190","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1039\/C8DT03923B","article-title":"Emerging platinum(IV) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment","volume":"48","author":"Wang","year":"2019","journal-title":"Dalton Trans"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:03:21Z","timestamp":1773277401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963426000110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["S1549963426000110"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2026.102910","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cisplatin(IV)-fatty acid prodrug-bound albumin nanoparticles: In vitro, in silico, and in vivo evaluation in breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2026.102910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102910"}}